I Underestimated Eli Lilly: Retatrutide Turns Upside From Expensive to Necessary
Eli Lilly’s next-generation obesity candidate retatrutide and a blistering Q2 performance force a reassessment. The market has priced growth into a premium multiple, but retatrutide’s efficacy (28.3% mean weight loss in Phase 3) plus robust cash generation and raised guidance make a compelling asymmetric long. This trade idea lays out an entry at $…